A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families
about
The 2588G-->C mutation in the ABCR gene is a mild frequent founder mutation in the Western European population and allows the classification of ABCR mutations in patients with Stargardt diseaseFounder mutations in the BRCA1 gene in Polish families with breast-ovarian cancerFounder populations and their uses for breast cancer genetics.BRCA1 and BRCA2 mutations in Scotland and Northern IrelandAshkenazi Jews and breast cancer: the consequences of linking ethnic identity to genetic diseaseNovel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancerHigh proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague areaThe frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populationsPrevalence of BRCA1 in a hospital-based population of Dutch breast cancer patientsA probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer familiesGenetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage ConsortiumMolecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological featuresMultiplex SNaPshot for detection of BRCA1/2 common mutations in Spanish and Spanish related breast/ovarian cancer familiesBRCA1 and BRCA2 germline mutation analysis in the Indonesian population.Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection.Founder effect at PGL1 in hereditary head and neck paraganglioma families from the Netherlands.Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.High frequency of BRCA1/2 germline mutations in 42 Belgian families with a small number of symptomatic subjectsPre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics.Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.BRCA1 mutations in southern EnglandCharacteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families.BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families.Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology.Identification of the prevalent BRCA1 and BRCA2 mutations in the female population of Puerto RicoEstablishing a program for individuals at high risk for breast cancer.Mutation analysis of BRCA1 gene in African-American patients with breast cancer.Population genetics of BRCA1 and BRCA2.Selection in the Ashkenazi Jewish Population Unlikely—Reply to Zlotogora and Bach.Mutations in context: implications of BRCA testing in diverse populations.Pathology of hereditary breast cancer.
P2860
Q24540182-A972CD5A-DC33-40C3-85E9-E55B3DB6A8E6Q24540270-8505DAA0-FE41-4DF7-82B1-6CF5CD232F5CQ24544179-D445BA86-6AA2-4F56-89CB-EE39384F19C1Q24650826-25074819-7782-4D0E-A93B-AD78F101D820Q24675652-869ECDE5-5195-45DF-B77C-EECAA454FFBCQ24796354-889F70F8-0E69-4C2A-B6B0-A5C2A8A63924Q24813558-AA6F1E2E-9F14-4A7D-89C7-C4099E5D5D05Q25257213-4F5737B4-66F9-4B93-8AC4-992EB2708227Q28384196-8A78ACE9-A694-4BA9-AEB4-E3BF51112F3BQ28384206-9742A7EC-7083-45AB-8569-01EF5C01490EQ29619206-4AFFA5F6-9579-4AE5-BF66-A8FF26B528B6Q33182341-A61AAB95-7653-4896-91E1-8F219E0D6D2BQ33289529-121901DA-2F12-467C-83C1-EB00EB8CA0EFQ33304489-1A269E50-3CBD-46A6-9CEC-1D178205694DQ34029011-F6C93191-DB36-4B21-8B26-C4A7E04CBFFDQ34386460-9F5532FE-1600-4D8B-8BA3-1F45F79C3BE2Q34387715-27817288-1B8A-40C2-A650-897401DEDD6DQ35432260-87CE2867-4158-4D6B-A21B-8596545DB5F4Q35443103-3E062572-0408-4F6B-879C-CFE31C4A1DFFQ36117690-B248C671-3867-431F-B3FC-703893D91692Q36292995-6052D2F2-D6E1-41EC-982A-5F8FFF7757F3Q36618998-4503E67C-B17C-4783-8442-490595251230Q36620818-95486367-BE17-4FED-9FC1-549296552D97Q36694756-EF072B41-56A2-4F71-AD75-7744E2CB8D6EQ36843211-76FB5D81-6973-422C-A528-DC73C4C656CEQ36849117-868FA206-23D0-4056-BE0D-A3852B9E08B3Q36983389-7EE035AF-98A4-4F49-B416-ACFEE4B752D5Q41734561-8C710E4D-BF85-4C8A-A61D-99F69CF8BCC6Q43109039-2EFF00FE-EDC5-4C72-B7E2-E83F8C76F8F8Q46864014-F8E63D84-77F1-42B1-8CB1-30516ED2A5CAQ47691368-1841F872-F8CB-4576-BD2A-E343A277A6CCQ55110010-3A2F2811-DA7A-4352-98E8-63F38814CC3D
P2860
A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families
description
1997 nî lūn-bûn
@nan
1997 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
A high proportion of novel mut ...... st and ovarian cancer families
@ast
A high proportion of novel mut ...... st and ovarian cancer families
@en
A high proportion of novel mut ...... st and ovarian cancer families
@nl
type
label
A high proportion of novel mut ...... st and ovarian cancer families
@ast
A high proportion of novel mut ...... st and ovarian cancer families
@en
A high proportion of novel mut ...... st and ovarian cancer families
@nl
prefLabel
A high proportion of novel mut ...... st and ovarian cancer families
@ast
A high proportion of novel mut ...... st and ovarian cancer families
@en
A high proportion of novel mut ...... st and ovarian cancer families
@nl
P2093
P2860
P1476
A high proportion of novel mut ...... st and ovarian cancer families
@en
P2093
A H van der Hout
A M van den Ouweland
A Petrij-Bosch
F Hogervorst
P2860
P304
P407
P577
1997-05-01T00:00:00Z